DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Denali Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.04+0.43 (+2.44%)
Close on Oct 19, 2026
- Market cap
- $3.38B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2015 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 157.9% | 9.2% | -45.7% | |
| Return on assets | – | 6.6% | -40.7% | |
| Current ratio | – | 20.86 | 9.16 | |
| Capex to revenue | – | 0.9% | – | |
| Diluted shares | 6M | 113M | 173M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Denali Therapeutics generated $1.57B from operations and spent $64.69M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.57B
Used
$64.69M
Capital expenditure$64.69M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-43.9%
×Asset turnover0.25×
×Equity multiplier1.26×
=Return on equity, FY2023-14.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -43.9% | 0.25× | 1.26× | -14.0% |
| FY2022 | -300.6% | 0.08× | 1.43× | -32.5% |
| FY2021 | -597.2% | 0.03× | 1.42× | -27.5% |
| FY2020 | 21.2% | 0.31× | 1.40× | 9.2% |
| FY2019 | -740.7% | 0.04× | 1.29× | -42.0% |
| FY2018 | -28.1% | 0.22× | 1.13× | -7.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$512.54M
- Cash generatingOperating cash flow above zero-$412.60M
- Return on assets improvedROA up on the prior year-36.6% → -37.3%
- Earnings backed by cashOperating cash flow above net income-$412.60M vs -$512.54M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose8.46 → 9.16
- No dilutionShare count did not rise164M → 173M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00